In biotech, one thing isn't going to change.
The "bread and butter" technology that makes up 90% of the pharmaceutical market – good, old-fashioned small molecules, created in the laboratory – isn't going anywhere.
Yes, incredibly innovative treatments like T-cell therapy and microbiome therapies (and firms like Bill Gates' new favorite $6 million company) are all having a huge impact on healthcare.
But we use small, synthetic molecules to create everything from aspirin and corticosteroids to sofosbuvir (Sovaldi) and ivacaftor (Kalydeco) – and we'll keep doing so for a long time to come.
The small molecule technique dates back to the 1890s, but that doesn't mean innovation cannot happen within that field. Scientists are always hard at work in the labs, creating cutting-edge drugs, often tailored to treat a very specific disease or subset of patients.
Meanwhile, I've turned up a tiny British company that's using its artificial intelligence (AI) platform discover promising small molecule treatments faster – and cheaper – than ever before.
I call it "biointelligence."
It's a perfect illustration of the "Convergence Economy" we talk so much about here. By combining two or more fields of tech – in this case biotech and AI – it's like a formula in which 1 + 1 = 3… and often a lot more that.
Today, we're going to learn all about this tiny company and its brand-new biointelligence technology.
This company is privately held – so if you ask, Wall Street will say you can't invest in it. But I've found a way you can.
In fact, I've found two ways.
Both of them will lead you to outsized returns – and hefty dividends.